Responding to growing pressure, ViiV Healthcare announced steps to widen access to its HIV prevention medicine in low- and ...

ViiV Healthcare sponsored events to address the climbing rates of HIV infections on HBCU campuses and the surrounding Black ...

The announcement marks another important milestone in our efforts to accelerate access to the only long-acting PrEP available ...

Responding to ViiV's announcement on long-acting cabotegravir , UNAIDS Executive Director Winnie Byanyima said:"New HIV ...

ViiV Healthcare’s latest HIV prevention campaign coincided with one of the biggest weekends of the year at Alabama State University.

ViiV Healthcare, a GSK-majority-owned HIV specialist, has committed to making at least two million doses of its long-acting ...

Note: ViiV’s announcement can be read on their site at ...

J&J and ViiV – majority-owned by GlaxoSmithKline – hope that the streamlined process will help boost take-up of Cabenuva, which became the first long-acting alternative to daily ART last year.

The company is committing to make at least 2 million doses of its long-acting PrEP therapy available in low- and middle-income countries next year and in 2026.

The European Commission has given a green light to the use of ViiV Healthcare’s Rukobia as a treatment for people with HIV that has developed resistance to other antiretroviral therapy (ART).

ViiV’s strategy for CAB LA for PrEP in L&MICs is to maximise rapid access and uptake for populations with highest unmet needs ...

During homecoming festivities at Alabama State University, a unique pharmaceutical company was on campus to promote HIV ...